Therapeutic options among broad-spectrum β-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae

Diagnostic Microbiology and Infectious Disease

Volumn 52, Issue 2, 2005, Pages 129-133

  Jones, Ronald N ^a,b   Fritsche, Thomas R ^a   Sader, Helio S ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cefepime; Levofloxacin; Resistance; S. pneumoniae

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; ASIA; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DRUG SURVEILLANCE PROGRAM; EUROPE; GENE MUTATION; GENE SEQUENCE; MICROBIAL POPULATION DYNAMICS; MUTATIONAL ANALYSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PACIFIC ISLANDS; PARENTERAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCREENING; STRAIN DIFFERENCE; STRAIN IDENTIFICATION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; WESTERN HEMISPHERE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; COMMUNITY-ACQUIRED INFECTIONS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PNEUMONIA, PNEUMOCOCCAL; POLYMERASE CHAIN REACTION; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 20444473866     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2004.12.009     Document Type: Article

References (24)

1. S.D. Brown, D.J. Farrell, and I. Morrissey Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study J. Clin. Microbiol. 42 2004 4980 4987
2. D. Chen, A. McGeer, J.C. de Azavedo, and D.E. Low The Canadian bacterial surveillance network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada N. Engl. J. Med. 341 1999 233 239
3. R. Davidson, R. Cavalcanti, J.L. Brunton, D.J. Bast, J.C. de Azavedo, P. Kibsey, C. Fleming, and D.E. Low Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia N. Engl. J. Med. 346 2002 747 750
4. G.M. Eliopoulos Quinolone resistance mechanisms in pneumococci Clin. Infect. Dis. 38 Suppl 4 2004 S350 S356
5. A.D. Fernandez, M.K. Elmore, and D.W. Metzger Azithromycin modulates murine immune responses to pneumococcal conjugate vaccine and inhibits nasal clearance of bacteria J. Infect. Dis. 190 2004 1762 1766
6. P.L. Ho, T.L. Que, D.N. Tsang, T.K. Ng, K.H. Chow, and W.H. Seto Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong Antimicrob. Agents Chemother. 43 1999 1310 1313
7. D.J. Hoban, G.V. Doern, A.C. Fluit, M. Roussel-Delvallez, and R.N. Jones Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999 Clin. Infect. Dis. 32 Suppl 2 2001 81 93
8. R.N. Jones Microbiology of newer fluoroquinolones: Focus on respiratory pathogens Diagn. Microbiol. Infect. Dis. 44 2002 213 220
9. R.N. Jones, A.H. Mutnick, and D.J. Varnam Impact of modified nonmeningeal Streptococcus pneumoniae interpretive criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: Report from the SENTRY Antimicrobial Surveillance Program (1997 to 2001) J. Clin. Microbiol. 40 2002 4332 4333
10. K.P. Klugman Vaccination: A novel approach to reduce antibiotic resistance Clin. Infect. Dis. 39 2004 649 651
11. K.P. Klugman, D.E. Low, J. Metlay, J.-C. Pechere, and K. Weiss Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities Int. J. Antimicrob. Agents 24 2004 411 422
12. J.R. Lonks, J. Garau, L. Gomez, M. Xercavins, A. Ochea de Echaguen, I.F. Gareen, P.T. Reiss, and A.A. Medeiros Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae Clin. Infect. Dis. 35 2002 556 564
13. L.A. Mandell, J.G. Bartlett, S.F. Dowell, T.M. File Jr, D.M. Musher, and C. Whitney Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults Clin. Infect. Dis. 37 2003 1405 1433
14. I. Morrissey, D.J. Farrell, S. Bakker, S. Buckridge, and D. Felmingham Molecular characterization and antimicrobial susceptibility of fluoroquinolone-resistant or -susceptible Streptococcus pneumoniae from Hong Kong Antimicrob. Agents. Chemother. 47 2003 1433 1435
15. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing [Document M7-A6] 2003 NCCLS Wayne (PA)
16. National Committee for Clinical Laboratory Standards Performance standards for antimicrobial susceptibility testing, 15th informational supplement [Document M100-S15] 2005 NCCLS Wayne (PA)
17. M.W.R. Pletz, L. McGee, J. Jorgensen, B. Beall, R.R. Facklam, C.G. Whitney, K.P. Klugman The Active Bacterial Core Surveillance Team Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: Evidence for clonal spread and the impact of conjugate pneumococcal vaccine Antimicrob. Agents Chemother. 48 2004 3491 3497
18. Pottumarthy S, Fritsche TR, Jones RN (2005) Comparative activity of oral and parenteral cephalosporins tested against multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1997-2003). Diagn Microbiol Infect Dis [in press].
19. J. Powis, A. McGeer, K. Green, O. Vanderkooi, K. Weiss, G. Zhanel, T. Mazzulli, M. Kuhn, D. Church, R. Davidson, K. Forward, D. Hoban, and A. Simor The Canadian Bacterial Surveillance Network D.E. Low In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002 Antimicrob. Agents Chemother. 48 2004 3304 3311
20. H.S. Sader, T.R. Fritsche, A.H. Mutnick, and R.N. Jones Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared to other orally administered antimicrobials tested against common respiratory tract pathogens Diagn. Microbiol. Infect. Dis. 47 2003 515 526
21. H.J. Smith, K.A. Nichol, D.J. Hoban, and G.G. Zhanel Stretching the mutant prevention concentration (MPC) beyond its limits J. Antimicrob. Chemother. 51 2003 1323 1325
22. H.J. Smith, A.M. Noreddin, C.G. Siemens, K.N. Schurek, J. Greisman, C.J. Hoban, D.J. Hoban, and G.G. Zhanel Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics/ pharmacodynamics Antimicrob. Agents Chemother. 48 2004 3630 3635
23. K. Weiss, C. Restieri, R. Gauthier, M. Laverdiere, A. McGeer, R.J. Davidson, L. Kilburn, D.J. Bast, J. de Azavedo, and D.E. Low A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae Clin. Infect. Dis. 33 2001 517 522
24. G.W. Wortmann, and S.P. Bennett Fatal meningitis due to levofloxacin-resistant Streptococcus pneumoniae Clin. Infect. Dis. 29 1999 1599 1600